Repetitive Thoughts in Fibromyalgia: Impact of Rumination on the Emotional and Cognitive Dimensions of Fibromyalgia

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03133455

Acronym

PRFM-1

Enrollment

107

Registered

2017-04-28

Start date

2015-09-16

Completion date

2017-11-26

Last updated

2025-09-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fibromyalgia

Keywords

Rumination

Brief summary

Dysfunctional chronic diffuse pain syndrome, concerning 2% of the French population, Fibromyalgia (FM) is classified either as a psychological disease or as a somatic disease. This dichotomous reasoning does not lead to a better understanding and does not allow the use or development of new psychological tools of care. The issue of the proximity between FM and depression highlighted by some authors and the presence of anxious comorbidities may arise at a different level, that of the transdiagnostic approach. Rumination is one of these transdiagnostic processes that are the subject of recent studies and one of the dimensions of which (abstract analytical rumination) is at work in depression and a number of psychopathologies. The investigator therefore wishes to explore the process of rumination and its abstract analytical dimension in FM and to explore its link with the depressive and anxious manifestations frequently associated with this disorder.

Interventions

OTHEREvaluate the link between an abstract / analytical thinking style and depressive manifestations in FM.

Evaluate the link between an abstract / analytical thinking style and depressive manifestations in FM.

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

OTHER

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* FM Criteria of the American College of Rheumatology ACR 1990. * Major Patients * free and informed consent signed * stable treatment for at least one month * Native French speaker * Patient covered by health insurance.

Exclusion criteria

* Patient deprived of liberty or protected major (under guardianship or curatorship)

Design outcomes

Primary

Measure	Time frame	Description
Analyze the rate of rumination and depression of a fibromyalgia patient using a questionnaire	1 hour	Analyze the rate of rumination and depression of a fibromyalgia patient using a questionnaire

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026